Phaseline

Companies › Genuine Seed Therapeutics (Zhuhai)

Genuine Seed Therapeutics (Zhuhai): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GST101
KRAS inhibitor
KRASPhase 1RAS-mutant Advanced Solid TumorsOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07868172GST101Phase 1RAS-mutant Advanced Solid TumorsOncologyOct 2028

Targets

KRAS (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Amgen Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.